Compare · LEVI vs SILO
LEVI vs SILO
Side-by-side comparison of Levi Strauss & Co (LEVI) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEVI and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- LEVI is the larger of the two at $7.92B, about 3467.2x SILO ($2.3M).
- LEVI has been more active in the news (8 items in the past 4 weeks vs 3 for SILO).
- LEVI has more recent analyst coverage (25 ratings vs 0 for SILO).
- Company
- Levi Strauss & Co
- Silo Pharma Inc.
- Price
- -
- -
- Market cap
- $7.92B
- $2.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 0
Levi Strauss & Co
Levi Strauss & Co. operates as an apparel company. It designs, markets, and sells jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories for men, women, and children in the Americas, Europe, and Asia. The company sells its products under the Levi's, Dockers, Signature by Levi Strauss & Co., and Denizen brands; and also licenses its Levi's and Dockers trademarks for various product categories, including footwear, belts, wallets and bags, outerwear, sweaters, dress shirts, kids wear, sleepwear, and hosiery. The company sells its products through third-party retailers, such as department stores, specialty retailers, third-party e-commerce sites, and franchisees who operate brand-dedicated stores; and directly to consumers through various formats, including company-operated mainline and outlet stores, company-operated e-commerce sites, and select shop-in-shops located in department stores and other third-party retail locations. It operates approximately 3,100 brand-dedicated stores and shop-in-shops. The company was founded in 1853 and is headquartered in San Francisco, California.
Latest LEVI
- Amendment: SEC Form SCHEDULE 13G/A filed by Levi Strauss & Co
- SEC Form 8-K filed by Levi Strauss & Co
- SEC Form 10-Q filed by Levi Strauss & Co
- Levi Strauss & Co. Reports Third-Quarter Results
- SEC Form 4 filed by Levi Strauss & Co
- Levi Strauss & Co filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Levi Strauss & Co. Appoints John Vandemore as Chief Financial Officer
- Levi Strauss & Co. to Webcast Third Quarter 2026 Earnings Conference Call
- Levi Strauss & Co filed SEC Form 8-K: Leadership Update
- Director Prime Joshua E was granted 106 shares, increasing direct ownership by 0.14% to 73,422 units (SEC Form 4)
Latest SILO
- SEC Form 8-K filed by Silo Pharma Inc.
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
- Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
- Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
- Silo Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Silo Pharma Inc.
- Silo Pharma Granted European Patent Covering Novel PTSD Therapy